S&P 500   4,210.24 (+2.13%)
DOW   33,309.51 (+1.63%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
S&P 500   4,210.24 (+2.13%)
DOW   33,309.51 (+1.63%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
S&P 500   4,210.24 (+2.13%)
DOW   33,309.51 (+1.63%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
S&P 500   4,210.24 (+2.13%)
DOW   33,309.51 (+1.63%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
NASDAQ:VRTX

Vertex Pharmaceuticals - VRTX Stock Forecast, Price & News

$295.77
-3.06 (-1.02%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$295.11
$301.80
50-Day Range
$245.39
$298.83
52-Week Range
$176.36
$301.80
Volume
1.43 million shs
Average Volume
1.70 million shs
Market Capitalization
$75.64 billion
P/E Ratio
23.91
Dividend Yield
N/A
Price Target
$290.05

Vertex Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.65 Rating Score
Upside/​Downside
1.9% Downside
$290.05 Price Target
Short Interest
Healthy
1.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.12
Upright™ Environmental Score
News Sentiment
0.27mentions of Vertex Pharmaceuticals in the last 14 days
Based on 42 Articles This Week
Insider Trading
Selling Shares
$48.49 M Sold Last Quarter
Proj. Earnings Growth
8.82%
From $12.36 to $13.45 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

300th out of 1,108 stocks

Pharmaceutical Preparations Industry

133rd out of 542 stocks

VRTX stock logo

About Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX opened at $298.83 on Wednesday. Vertex Pharmaceuticals has a 1-year low of $176.36 and a 1-year high of $301.73. The company has a debt-to-equity ratio of 0.05, a current ratio of 3.84 and a quick ratio of 3.72. The business has a fifty day moving average price of $278.51 and a 200-day moving average price of $262.00. The company has a market capitalization of $76.43 billion, a PE ratio of 24.16, a PEG ratio of 2.13 and a beta of 0.45.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The pharmaceutical company reported $3.60 EPS for the quarter, topping the consensus estimate of $3.12 by $0.48. Vertex Pharmaceuticals had a return on equity of 31.22% and a net margin of 38.26%. The company had revenue of $2.20 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same period last year, the company earned $2.80 EPS. Vertex Pharmaceuticals's revenue for the quarter was up 22.5% on a year-over-year basis. As a group, equities analysts expect that Vertex Pharmaceuticals will post 12.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on VRTX. SVB Leerink began coverage on Vertex Pharmaceuticals in a research note on Monday, May 23rd. They issued a "market perform" rating and a $265.00 price target for the company. Maxim Group raised Vertex Pharmaceuticals from a "hold" rating to a "buy" rating and set a $325.00 price target for the company in a research note on Wednesday, June 1st. Morgan Stanley raised their price target on Vertex Pharmaceuticals from $250.00 to $253.00 and gave the stock an "equal weight" rating in a research note on Monday. UBS Group raised their price target on Vertex Pharmaceuticals from $258.00 to $325.00 in a research note on Wednesday, April 13th. Finally, Cowen raised their price objective on Vertex Pharmaceuticals from $305.00 to $310.00 in a research report on Monday, June 13th. Six investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $290.05.

Insider Buying and Selling

In related news, Chairman Jeffrey M. Leiden sold 132,079 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, July 25th. The stock was sold at an average price of $281.38, for a total value of $37,164,389.02. Following the completion of the sale, the chairman now directly owns 2,423 shares in the company, valued at approximately $681,783.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Sangeeta N. Bhatia sold 621 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $278.77, for a total value of $173,116.17. Following the completion of the sale, the director now directly owns 5,282 shares in the company, valued at approximately $1,472,463.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman Jeffrey M. Leiden sold 132,079 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, July 25th. The stock was sold at an average price of $281.38, for a total value of $37,164,389.02. Following the completion of the sale, the chairman now owns 2,423 shares of the company's stock, valued at $681,783.74. The disclosure for this sale can be found here. In the last ninety days, insiders sold 162,254 shares of company stock worth $45,899,243. 0.40% of the stock is owned by corporate insiders.

Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Stock News Headlines

Vertex Pharmaceuticals Lifts FY22 Product Revenue Outlook
Vertex Pharmaceuticals Inc. Reveals Rise In Q2 Bottom Line
12 Best Healthcare Stocks To Buy Now
Where Will CRISPR Therapeutics Be in 1 Year?
My Top Stock to Buy If We're in a Recession
See More Headlines
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Company Calendar

Last Earnings
8/04/2022
Today
8/10/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VRTX
CUSIP
92532F10
Employees
3,900
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$290.05
High Stock Price Forecast
$365.00
Low Stock Price Forecast
$222.00
Forecasted Upside/Downside
-1.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.65
Research Coverage
17 Analysts

Profitability

Net Income
$2.34 billion
Pretax Margin
47.10%

Debt

Sales & Book Value

Annual Sales
$7.57 billion
Cash Flow
$12.97 per share
Book Value
$39.72 per share

Miscellaneous

Free Float
254,733,000
Market Cap
$75.64 billion
Optionable
Optionable
Beta
0.45

Social Links


Key Executives














VRTX Stock - Frequently Asked Questions

Should I buy or sell Vertex Pharmaceuticals stock right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRTX shares.
View VRTX analyst ratings
or view top-rated stocks.

What is Vertex Pharmaceuticals' stock price forecast for 2022?

17 brokerages have issued 12 month target prices for Vertex Pharmaceuticals' shares. Their VRTX share price forecasts range from $222.00 to $365.00. On average, they anticipate the company's stock price to reach $290.05 in the next year. This suggests that the stock has a possible downside of 2.2%.
View analysts price targets for VRTX
or view top-rated stocks among Wall Street analysts.

How have VRTX shares performed in 2022?

Vertex Pharmaceuticals' stock was trading at $219.60 at the beginning of 2022. Since then, VRTX shares have increased by 35.0% and is now trading at $296.47.
View the best growth stocks for 2022 here
.

When is Vertex Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our VRTX earnings forecast
.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) issued its earnings results on Thursday, August, 4th. The pharmaceutical company reported $3.60 EPS for the quarter, topping analysts' consensus estimates of $3.12 by $0.48. The pharmaceutical company had revenue of $2.20 billion for the quarter, compared to the consensus estimate of $2.13 billion. Vertex Pharmaceuticals had a trailing twelve-month return on equity of 31.22% and a net margin of 38.26%. Vertex Pharmaceuticals's quarterly revenue was up 22.5% compared to the same quarter last year. During the same period last year, the firm earned $2.80 earnings per share.
Read the conference call transcript
.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $8.60 billion-$8.80 billion, compared to the consensus revenue estimate of $8.58 billion.

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Loomis Sayles & Co. L P (1.74%), Jennison Associates LLC (0.69%), Swiss National Bank (0.43%), Sumitomo Mitsui Trust Holdings Inc. (0.36%), Lazard Asset Management LLC (0.34%) and Vaughan Nelson Investment Management L.P. (0.34%). Insiders that own company stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Joy Liu, Kristen Ambrose, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee.
View institutional ownership trends
.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $296.47.

How much money does Vertex Pharmaceuticals make?

Vertex Pharmaceuticals (NASDAQ:VRTX) has a market capitalization of $75.82 billion and generates $7.57 billion in revenue each year. The pharmaceutical company earns $2.34 billion in net income (profit) each year or $12.37 on an earnings per share basis.

How many employees does Vertex Pharmaceuticals have?

The company employs 3,900 workers across the globe.

Does Vertex Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vectrus, Vertex Farmaceutica do Brasil LTDA, Vertex Holdings Inc., Vertex Pharmaceuticals (Australia) Pty. Ltd., Vertex Pharmaceuticals (CH) GmbH, Vertex Pharmaceuticals (Canada) Incorporated, Vertex Pharmaceuticals (Cayman 509) Limited, Vertex Pharmaceuticals (Cayman 765) Limited, Vertex Pharmaceuticals (Cayman 787) Limited, Vertex Pharmaceuticals (Cayman III) Limited, Vertex Pharmaceuticals (Cayman) Limited, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC, Vertex Pharmaceuticals (Distribution) Incorporated, Vertex Pharmaceuticals (Europe) Limited, Vertex Pharmaceuticals (France) SAS, Vertex Pharmaceuticals (Germany) GmbH, Vertex Pharmaceuticals (Ireland) Limited, Vertex Pharmaceuticals (Italy) S.r.L., Vertex Pharmaceuticals (Netherlands) B.V., Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal), Vertex Pharmaceuticals (Puerto Rico) LLC, Vertex Pharmaceuticals (San Diego) LLC, Vertex Pharmaceuticals (Singapore) Pte. Ltd., Vertex Pharmaceuticals (Spain) S.L., Vertex Pharmaceuticals (Sweden) AB, Vertex Pharmaceuticals (U.K.) Limited, Vertex Pharmaceuticals GmbH, Vertex Pharmaceuticals Single Member Societe Anonyme, and Vertex Securities Corporation.
Read More

When was Vertex Pharmaceuticals founded?

Vertex Pharmaceuticals was founded in 1989.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The official website for the company is www.vrtx.com. The pharmaceutical company can be reached via phone at (617) 341-6100, via email at investorinfo@vrtx.com, or via fax at 617-576-2109.

This page (NASDAQ:VRTX) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.